Dry eye: steps to success

Article

Allan Slomovic, University of Toronto, Canada, speaking at a continuing education symposium on dry eye diagnosis and management, outlined a five-step diagnostic algorithm for dry eye.

Allan Slomovic, University of Toronto, Canada, speaking at a continuing education symposium on dry eye diagnosis and management, outlined a five-step diagnostic algorithm for dry eye.

The first step is to obtain a history of dry eye symptoms, including both ocular and medical histories. Next, determine tear break-up time, values below 10 seconds are suspect and values below one second are abnormal. The third step is to conduct the Schirmer's test, preferably without anaesthesia. In the fourth step, the clinician performs diagnostic eye staining with fluorescein, lissamine green, or rose bengal. Fifth, test for serum antibodies, which is particularly helpful if Sjogrens Syndrome aqueous tear deficiency dry eye (ATD) is suspected. The last step is meibomian gland evaluation.

"With this algorithm, you can reliably diagnose a dry eye and determine if it is caused by ATD or evaporative dry eye tear deficiency (ETD) or both," Dr Slomovic said. The algorithm results also help the clinician evaluate severity, which in turn drives the choice of treatment.

Among the dry eye treatment options, lubricants are the first choice, said Alejandro Aguilar, MD, director of the ocular surface department, Grupo Medico Las Lomas in Martinez, Argentina, and associate professor of ophthalmology, Universidad del Salvador, Buenos Aires. Lubricants provide a protective epithelial shield, integrate with the tear film, are long-lasting and comfortable, facilitate restoration and cellular replacement, maintain ocular surface health and prevent future damage, Dr Aguilar said.

Maurizio Rolando, MD, associate professor in the department of neurosciences, ophthalmology, and genetics at the University of Genoa, Italy, advises clinicians to be dynamic, adjusting patients' therapy to changing conditions and to teach preventive measures such as increasing humidity in the home and wearing protective glasses.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.